Can-Fite BioPharma Ltd. AMEX:CANF

Founder-led company

Can-Fite BioPharma Ltd. stock price today

$0.65
-0.93
-58.86%
Financial Health
0
1
2
3
4
5
6
7
8
9

Can-Fite BioPharma Ltd. stock price monthly change

-54.47%
month

Can-Fite BioPharma Ltd. stock price quarterly change

-54.47%
quarter

Can-Fite BioPharma Ltd. stock price yearly change

-28.18%
year

Can-Fite BioPharma Ltd. key metrics

Market Cap
9.08M
Enterprise value
4.26M
P/E
-0.57
EV/Sales
4.69
EV/EBITDA
-0.37
Price/Sales
8.71
Price/Book
1.06
PEG ratio
-0.04
EPS
-1.81
Revenue
743K
EBITDA
-8.19M
Income
-7.47M
Revenue Q/Q
-21.31%
Revenue Y/Y
-8.27%
Profit margin
-1247.41%
Oper. margin
-1241.58%
Gross margin
0%
EBIT margin
-1241.58%
EBITDA margin
-1102.96%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Can-Fite BioPharma Ltd. stock price history

Can-Fite BioPharma Ltd. stock forecast

Can-Fite BioPharma Ltd. financial statements

Can-Fite BioPharma Ltd. (AMEX:CANF): Profit margin
Mar 2023 196K -2.38M -1218.37%
Jun 2023 196K -1.67M -852.04%
Sep 2023 196K -1.76M -898.98%
Dec 2023 155K -1.65M -1065.81%
Can-Fite BioPharma Ltd. (AMEX:CANF): Analyst Estimates
2025 900K -4.72M -525.54%
2026 800K -213.05K -26.63%
2027 43.34M 4.98M 11.5%
2028 310.88K 9.97M 3207.35%
  • Analysts Price target

  • Financials & Ratios estimates

Can-Fite BioPharma Ltd. (AMEX:CANF): Earnings per share (EPS)
2024-06-27 -0.4 -0.65
2024-09-26 -0.4 -0.4
2024-12-05 -0.27 -0.27
0%
Yield TTM
Can-Fite BioPharma Ltd. (AMEX:CANF): Payout ratio
Payout ratio 0%
Can-Fite BioPharma Ltd. (AMEX:CANF): Dividend Yield
2019
2020
2021 0.01%
2022 0.05%
2023
Can-Fite BioPharma Ltd. (AMEX:CANF): Debt to assets
Mar 2023 13489000 4.99M 37.04%
Jun 2023 11032000 4.15M 37.69%
Sep 2023 9169000 3.93M 42.91%
Dec 2023 9989000 3.74M 37.5%
Can-Fite BioPharma Ltd. (AMEX:CANF): Cash Flow
Mar 2023 0 0 0
Jun 2023 95K 0 0
Sep 2023 0 0 0
Dec 2023 0 0 0

Can-Fite BioPharma Ltd. alternative data

Can-Fite BioPharma Ltd. (AMEX:CANF): Employee count
Aug 2023 8
Sep 2023 8
Oct 2023 8
Nov 2023 8
Dec 2023 8
Jan 2024 8
Feb 2024 8
Mar 2024 8
Apr 2024 8
May 2024 8
Jun 2024 8
Jul 2024 8

Can-Fite BioPharma Ltd. other data

0.01% -0.05%
of CANF is owned by hedge funds
4.86K -37.84K
shares is hold by hedge funds
Patent
Grant
Filling date: 26 Aug 2020 Issue date: 5 Apr 2022
Application
Filling date: 5 Jan 2020 Issue date: 17 Mar 2022
Application
Filling date: 16 Sep 2018 Issue date: 11 Mar 2021
Application
Filling date: 26 Aug 2020 Issue date: 10 Dec 2020
Grant
Filling date: 22 May 2018 Issue date: 22 Sep 2020
Insider Compensation
Dr. Pnina Fishman Ph.D. (1948) Scientific Founder, Chief Executive Officer & Director
$598,000
Mr. Motti Farbstein (1964) Chief Operating & Financial Officer
$415,000
Dr. Sari Fishman Ph.D. (1972) Vice President of Bus. Devel.
$286,000
Monday, 30 December 2024
globenewswire.com
Monday, 9 December 2024
zacks.com
Friday, 22 November 2024
accesswire.com
Monday, 11 November 2024
globenewswire.com
Monday, 4 November 2024
globenewswire.com
Friday, 18 October 2024
globenewswire.com
Wednesday, 9 October 2024
globenewswire.com
Monday, 16 September 2024
globenewswire.com
Thursday, 29 August 2024
globenewswire.com
Friday, 9 August 2024
accesswire.com
Thursday, 8 August 2024
globenewswire.com
Monday, 29 July 2024
globenewswire.com
Wednesday, 17 July 2024
globenewswire.com
Thursday, 11 July 2024
globenewswire.com
Monday, 24 June 2024
businesswire.com
Monday, 10 June 2024
businesswire.com
Wednesday, 5 June 2024
businesswire.com
Wednesday, 29 May 2024
businesswire.com
Monday, 27 May 2024
businesswire.com
Thursday, 23 May 2024
businesswire.com
Monday, 13 May 2024
businesswire.com
Friday, 10 May 2024
accesswire.com
Monday, 6 May 2024
businesswire.com
Thursday, 25 April 2024
businesswire.com
Monday, 15 April 2024
businesswire.com
Wednesday, 3 April 2024
businesswire.com
Monday, 1 April 2024
Newsfile Corp
Wednesday, 22 November 2023
Zacks Investment Research
Tuesday, 21 November 2023
PennyStocks
Friday, 27 October 2023
Zacks Investment Research
  • What's the price of Can-Fite BioPharma Ltd. stock today?

    One share of Can-Fite BioPharma Ltd. stock can currently be purchased for approximately $0.65.

  • When is Can-Fite BioPharma Ltd.'s next earnings date?

    Can-Fite BioPharma Ltd. is estimated to report earnings on Thursday, 28 Aug 2025.

  • Does Can-Fite BioPharma Ltd. pay dividends?

    No, Can-Fite BioPharma Ltd. does not pay dividends.

  • How much money does Can-Fite BioPharma Ltd. make?

    Can-Fite BioPharma Ltd. has a market capitalization of 9.08M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 8.27% to 743K US dollars. Can-Fite BioPharma Ltd. made a loss 7.63M US dollars in net income (profit) last year or -$0.27 on an earnings per share basis.

  • What is Can-Fite BioPharma Ltd.'s stock symbol?

    Can-Fite BioPharma Ltd. is traded on the AMEX under the ticker symbol "CANF".

  • What is Can-Fite BioPharma Ltd.'s primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Can-Fite BioPharma Ltd.?

    Shares of Can-Fite BioPharma Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Can-Fite BioPharma Ltd.'s key executives?

    Can-Fite BioPharma Ltd.'s management team includes the following people:

    • Dr. Pnina Fishman Ph.D. Scientific Founder, Chief Executive Officer & Director(age: 77, pay: $598,000)
    • Mr. Motti Farbstein Chief Operating & Financial Officer(age: 61, pay: $415,000)
    • Dr. Sari Fishman Ph.D. Vice President of Bus. Devel.(age: 53, pay: $286,000)
  • Is Can-Fite BioPharma Ltd. founder-led company?

    Yes, Can-Fite BioPharma Ltd. is a company led by its founder Dr. Pnina Fishman Ph.D..

  • How many employees does Can-Fite BioPharma Ltd. have?

    As Jul 2024, Can-Fite BioPharma Ltd. employs 8 workers.

  • When Can-Fite BioPharma Ltd. went public?

    Can-Fite BioPharma Ltd. is publicly traded company for more then 12 years since IPO on 6 Nov 2012.

  • What is Can-Fite BioPharma Ltd.'s official website?

    The official website for Can-Fite BioPharma Ltd. is canfite.com.

  • How can i contact Can-Fite BioPharma Ltd.?

    Can-Fite BioPharma Ltd. can be reached via phone at +972 3 924 1114.

Can-Fite BioPharma Ltd. company profile:

Can-Fite BioPharma Ltd.

canfite.com
Exchange:

AMEX

Full time employees:

8

Industry:

Biotechnology

Sector:

Healthcare

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

10 Bareket Street
Petah Tikva, 4951778

CIK: 0001536196
ISIN: US13471N3008
CUSIP: 13471N201